SBIR/STTR Research Award

Developing a paper based diagnostic test for sickle cell disease

Award identifier a4109acdb4d1392d1b20d83960e6ec0e976ea1dcabd9d1e379763527637e8320Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$997,560

Program and phase

SBIR · Phase II

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
HALCYON BIOMEDICAL INC
Proposal award date
2016-09-06
Contract end date
2019-06-30
UEI
C15ACBHQ4P67
Solicitation number
HL14-010
Topic code
NHLBI

Research abstract

PROJECT SUMMARY ABSTRACT More than of the global burden of sickle cell disease SCD is carried by the low income developing countries of sub Saharan Africa where incidence at birth can be as high as for SCD and for sickle trait SCD is particularly lethal to young children accounting for up to of under mortality in countries with the highest prevalence of the disease Data from pilot programs in Africa demonstrate that most of these deaths can be prevented with inexpensive treatments e g penicillin prophylaxis pneumococcal immunizations malaria bed nets and education about the importance of seeking medical attention for fever provided SCD could be diagnosed early in life In our Phase I work we have successfully developed a simple and inexpensive paper based test for the diagnosis of SCD in infants and young children andgt months old Our test enables the diagnosis via visual interpretation of the stain pattern produced on chromatography paper by a droplet of blood mixed with hemoglobin Hb solubility buffer The current version of the paper based SCD test kit is completely equipment and electricity free requires only a L blood sample costs andlt $ per test can be completed in min and is unaffected by severe anemia high HbF elevated ambient temperature or humidity It has a limit of detection of andlt HbS and was able to detect the presence of any HbS sickle cell trait or disease in patient samples with sensitivity and specificity in a pre clinical study in a resource limited setting n Cabinda Angola In our laboratory the test was able to diagnose SCD with sensitivity and specificity n In Phase II we propose to develop a complete self contained diagnostic kit and to demonstrate its diagnostic accuracy in a pivotal clinical trial across multiple sites in several countries in sub Saharan Africa We will first evaluate the feasibility of using a prototype kit for diagnosing SCD in the target patient population of children presenting with acute illness to Hospital Provincial de Cabinda We will also collect input on design and usability of the test s components and instructions from the site personnel to inform parallel development of the finished marketable diagnostic kit We will then work with our contract manufacturing partners to develop a version of the diagnostic kit that is optimized for mass production regulatory trials and subsequent marketing This iterative process will be continually informed by research and development in our laboratory the usability data from the Cabinda site and advice from our marketing and distribution partners Finally we will demonstrate the diagnostic accuracy of the finished marketable SCD test kit in a pivotal clinical trial in sub Saharan Africa We have to date identified well qualified clinical sites Morogoro Tanzania Bamako Mali Lusaka Zambia Ibadan Nigeria and Cabinda Angola each highly interested in participating in our trial We will work closely with our Steering Committee and the FDA to finalize the design of the proposed trial Public Health Relevance Most children born with sickle cell disease in sub Saharan Africa die in early childhood from causes that could be easily prevented through simple and inexpensive prophylaxis if their disease was diagnosed soon after birth Universal screening of newborns is impractical in low income countries due to a large number of out of hospital births and the prohibitive cost of conventional testing methods This highly innovative project plans to develop and commercialize an ultra low cost paper based diagnostic test for sickle cell disease to enable screening infants and young children during their first visit to a local clinic

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (1992–2020). Reported award amounts total $3,696,303. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.